

Gene promoter of apoptosis inhibitory protein IAP2: identification of enhancer elements and activation by severe hypoxia

Zheng DONG¹, Junichiro NISHIYAMA, Xiaolan YI, Manjeri A. VENKATACHALAM, Michael DENTON, Sumin GU, Senlin LI and Mei QIANG

Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, U.S.A.

Inhibitors of apoptosis (IAPs) antagonize cell death and regulate the cell cycle. One mechanism controlling IAP expression is translation initiation through the internal ribosome entry sites. Alternatively, IAP expression can be regulated at the transcription level. We showed recently the activation of IAP2 transcription by severe hypoxia. To pursue this regulation, we have cloned the full-length cDNA of rat IAP2, and have isolated and analysed the promoter regions of this gene. The cDNA encodes a protein of 589 amino acids, exhibiting structural features of IAP. In rat tissues, a major IAP2 transcript of ≈ 3.5 kb was detected. We subsequently isolated 3.3 kb of the proximal 5'-flanking regions of this gene, which showed significant promoter activity. Of interest, 5' sequential deletion of the promoter sequence identified an enhancer of ≈ 200 bp. Deletion

of cAMP-response-element-binding protein (CREB) sites in the enhancer sequence diminished its activity. Finally, the IAP2 gene promoter was activated significantly by severe hypoxia and not by CoCl_2 or desferrioxamine, pharmacological inducers of hypoxia-inducible factor-1. In conclusion, in this study we have cloned the full-length cDNA of rat IAP2, and for the first time we have isolated and analysed promoter sequences of this gene, leading to the identification of enhancer elements. Moreover, we have demonstrated activation of the gene promoter by severe hypoxia, a condition shown to induce IAP2. These findings provide a basis for further investigation of gene regulation of IAP2, a protein with multiple functions.

Key words: cell death, gene regulation, hypoxia-inducible factor-1.

INTRODUCTION

The inhibitors of apoptosis (IAPs) are a novel family of proteins that suppress apoptosis triggered by a variety of stimuli [1–5]. Recent studies suggest that IAPs may have other functions as well. For example, XIAP, the prototype of mammalian IAP, interacts and modulates the signalling cascade initiated by transforming growth factor β [6,7]. The newly discovered IAP family member Survivin has been shown to participate in cell-cycle control, specifically cytokinesis [8–11]. In addition, ubiquitin ligase activity has been shown for several IAPs, which may determine proteasome-mediated turnover of regulatory molecules for cell death or survival [12,13]. Thus, this family of proteins may play important roles in various physiological and pathogenic processes, including oncogenesis, neurodegeneration and ischaemic disease [14–16].

Originally identified in baculovirus, IAP has been cloned from human, mouse, pig, chicken, *Drosophila* and lately from rat [2,17–24]. In human, at least seven kinds of IAP have been identified, including XIAP, human IAPs (HIAPs) 1 and 2, neuronal IAP (NIAP), Survivin, BIR-repeat-containing ubiquitin-conjugating enzyme (BRUCE) and melanoma IAP (ML-IAP) [2,25]. Structural features of these proteins include the presence at their N-termini of up to three imperfect amino acid repeats approx. 70 residues in length, termed baculovirus IAP repeat (BIR). BIR is a sequence motif that is unique to IAP and, despite controversy [26–28], might be critical for their anti-apoptotic property under certain conditions [29,30]. In addition,

a RING finger is usually present near the IAP C-termini, which might be involved in protein–DNA as well as protein–protein interactions [31], and has been shown to be responsible for the ubiquitin-protein ligase activity of IAP [12,32].

Gene regulation of IAP has been implicated in cancer, neurodegenerative disorders and ischaemic diseases [14–16]. Recent studies have demonstrated an important mechanism governing XIAP expression at the level of translation initiation [33]. A sequence of 162 nucleotides has been identified in the 5'-untranslated region of XIAP mRNA, which acts as an internal ribosome entry site and facilitates protein expression even under cellular stresses such as serum deprivation and γ -irradiation. On the other hand, expression of specific IAPs can be regulated at the transcriptional level as well. IAPs 1 and 2 and XIAP are transcribed under the direction of the transcription factor nuclear factor κ B, in response to cytokine stimulation [24,34]. Our recent observations showed a striking induction of IAP2 by severe hypoxia [35]. The induction depends on gene transcription, and yet can be dissociated from the ubiquitous hypoxia-responsive transcription factor hypoxia-inducible factor 1 (HIF-1). Investigation of IAP gene regulation at the transcription level has been hindered, mainly due to the lack of information on promoters of these genes. In the current study, we have initially isolated the full-length cDNA of IAP2 from the rat kidney proximal tubular cells. With the cDNA sequence, we have subsequently isolated 3.3 kb proximal 5'-flanking regions of the rat IAP2 gene, by the technique of genomic walking. Analysis of the 3.3 kb genomic sequence demonstrated significant promoter activities. Within

Abbreviations used: EMSA, electrophoretic mobility-shift assay; HIF-1, hypoxia-inducible factor 1; IAP, inhibitor of apoptosis protein; BIR, baculovirus IAP repeat; RACE, rapid amplification of cDNA ends; RPTC, rat kidney proximal tubular cell; CREB, cAMP-response-element-binding protein; ATF, activating transcription factor.

¹ To whom correspondence should be addressed (e-mail dong@uthscsa.edu).

The nucleotide sequences of rat IAP2 cDNA and promoter regions reported in this paper have been submitted to the GenBank Nucleotide Sequence Database under the accession numbers AF190020 and AY027668.

the promoter regions, we have identified an enhancer sequence with critical cAMP-response-element-binding protein (CREB) elements that may regulate IAP2 gene expression. Of significance, the current study has provided the first evidence that the IAP2 promoter is activated by severe hypoxia, a condition triggering IAP2 gene expression. These results have laid the basis for further investigation of IAP2 gene regulation under various pathophysiological situations.

MATERIALS AND METHODS

Cell culture

Rat kidney proximal tubular cells (RPTCs) were obtained from Dr U. Hopfer at Case Western Reserve University (Cleveland, OH, U.S.A.) and maintained as described in our previous studies [35,36]. Other cells, including PC12, 3T3 and HEK-293 cells, were purchased from the A.T.C.C. (Manassas, VA, U.S.A.) and maintained following the specified procedures. Cell-culture media were purchased from Gibco Life Technologies (Rockville, MD, U.S.A.).

Hypoxic incubation

Cells were exposed to severe hypoxia as described previously [35,36]. Briefly, cells were washed with PBS and transferred to an anaerobic chamber with 85% N₂/10% H₂/5% CO₂. Incubation medium was then changed to Krebs/Ringer bicarbonate buffer that had been pre-equilibrated with 95% N₂/5% CO₂. EC Oxyrase, a biocatalytic oxygen-reducing agent, was added at 1.2 units/ml to the incubation medium to consume residual O₂ and maximize the degree of hypoxia.

Isolation of full-length cDNA of rat IAP2 by rapid amplification of cDNA ends (RACE)

RACE is a PCR-based technique for isolation of full-length cDNA of specific genes [37,38]. For RACE, a short stretch of sequence in the gene's cDNA should be available. Thus we initially isolated a cDNA fragment of rat IAP2 by reverse transcriptase PCR. Total RNA was isolated from RPTCs with TRI reagent (Molecular Research Center, Cincinnati, OH, U.S.A.). Using the RNA as templates, reverse transcriptase PCR was performed with primers (F1 and R1 in Table 1) designed according to the conservations between human and mouse IAP2 (GenBank accession numbers U88909 and U45879). This reverse transcriptase PCR amplified a cDNA fragment of \approx 470 bp with significant homology to mouse and human IAP2. Based on the sequence of the 470 bp fragment, rat IAP2 gene-specific primers were designed for RACE reactions (see Table 1 for primer sequences). For 3'-RACE, the oligo-dT adaptor primer was used for reverse transcription of total RNA isolated from RPTCs. The synthesized cDNA was then subjected to a first round of PCR amplification using the primer F2 and the adaptor primer R2. An aliquot of the PCR products was used subsequently as templates for the second round of (nested) PCR with primers F3 and R2.

After these two rounds of PCR, a major cDNA fragment of \approx 1.5 kb was amplified. 5'-RACE of rat IAP2 was accomplished with the Marathon™ cDNA amplification kit (Clontech, Palo Alto, CA, U.S.A.), following the manufacturer's instructions. Briefly, total RNA was isolated from RPTCs, and poly (A)⁺ RNA purified with PolyAtract mRNA isolation system (Promega, Madison, WI, U.S.A.). First-strand DNA was synthesized through reverse transcription of poly (A)⁺ RNA using avian myeloblastosis virus reverse transcriptase and a docking oligo-dT primer. Double-stranded DNA was synthesized

Table 1 Primers for RACE reactions

F1–F6, forward (sense) primers; R1–R6, reverse (antisense) primers. Primers F1 and R1 were designed on the basis of conservations between human and mouse IAP2 to amplify a 470 bp fragment of rat IAP2 cDNA by reverse transcriptase PCR. The oligo-dT adaptor primer was used for reverse transcription of RNA to generate cDNA templates for 3'-RACE. Primer pairs F2/R2 and F3/R2 were used for the primary and nested PCR reactions in 3'-RACE. Primer pairs F4/R1 and F5/R5 were used for the primary and nested PCR reactions in 5'-RACE. Primers F6 and R6 were designed according to the full-length cDNA isolated by RACE to amplify the coding region of rat IAP2.

Primer	Sequence
F1	5'-GCCCTCTTAATTCTAGAGCAG-3'
R1	5'-ACATCTCAAGCCACCATACA-3'
Oligo-dT	5'-GGCCACGGCTCGACTAGTAC (dT) ₁₇ -3'
F2	5'-GAGCAGCTTGCAAGTGGTGGGA-3'
R2	5'-GGCCACGGCTCGACTAGTAC-3'
F3	5'-GTTGTGATGGTGGCTTGAGATG-3'
F4	5'-CCATCCTAATACGACTCATATAGGGC-3'
F5	5'-ACTCACTATAGGGCTCGAGCGGC-3'
R5	5'-CTCCAGGCCCTGTGTAGTAGA-3'
F6	5'-GAAGTAGTGAGGAGCTTCAT-3'
R6	5'-CTGCGTAGCGTGAATCAGTA-3'

subsequently using a cocktail of *Escherichia coli* DNA polymerase I, RNase H and DNA ligase. The double-stranded DNA was then ligated to an adaptor sequence (5'-CTA ATA CGA CTC ACT ATA GGG CTC GAG CGG CCG CCC GGG CAG GT-3'). The ligated double-stranded DNA was used as a template for 5'-RACE reactions.

The first-round PCR of 5'-RACE was carried out using the adaptor primer F4 and the rat IAP2 gene-specific primer R1. An aliquot of the PCR products was then used as a template for the second-round PCR using the nested adaptor primer F5 and the nested gene-specific primer R5. The 5'-RACE reactions led to the amplification of a major cDNA fragment of \approx 1.7 kb. Products from 3'- and 5'-RACE were gel-purified and sequenced, showing significant homology to human and mouse IAP2. Sequences of the RACE products were aligned with the 470 bp fragment to obtain the sequence of full-length cDNA for rat IAP2.

Isolation of the proximal 5'-flanking sequence of rat IAP2 by genomic walking

Genomic walking is a PCR-based technique for cloning of unknown genomic DNA from a known sequence, which has been used widely to isolate promoters of genes for which only the cDNA sequence is available [39,40]. GenomeWalker kits were purchased from Clontech to isolate the proximal 5'-flanking regions of rat IAP2, following the manufacturer's instructions. Briefly, five aliquots of rat genomic DNA were digested separately by five restriction enzymes (*EcoRV*, *ScaI*, *DraI*, *PvuII* and *SspI*) to generate five genomic DNA pools (DL-1–DL-5). Fragments in the DNA pools were then ligated to an adaptor sequence (5'-GTA ATA CGA CTC ACT ATA GGG CAC GCG TGG TCG ACG GCC CGG GCT GGT-3'). The ligated DNA pools were used as templates for two rounds of PCR (primary and nested) with gene-specific primers and adaptor primers (see Table 2 for primers used in genomic walking). For the first genomic walking, gene-specific primers were designed according to the 5'-end sequence of rat IAP2 cDNA. The DNA fragments amplified by the PCR reactions were gel-purified, cloned into pGEM-T-easy vectors and sequenced. Whether the fragments were immediately upstream of the cDNA was verified by sequence

Table 2 Primers for genomic walking

Gene-specific primers (GSPs) for the first genomic walking were designed on the basis of the rat caspase-9 cDNA sequence isolated by RACE reactions. Other GSPs were designed based on the sequences of DNA fragments amplified by earlier genomic walking. Adaptor primers (AP1, AP2) were designed according to the adaptor sequence ligated to the digested genomic DNA.

Primer	Sequence
GSP-1 for first walking	5'-CTCTAAAGTGGGTACATCAACTGC-3'
GSP-2 for first walking	5'-ACATCTGGTCAACAGACAGTATTTG-3'
GSP-1 for second walking	5'-GGAACAGGCTACCAACAGGCTCCT-3'
GSP-2 for second walking	5'-CTTGACTGGAGACAAAAGGCACCTG-3'
GSP-1 for third walking	5'-GTCTCACAGACTACTGGACGCAAG-3'
GSP-2 for third walking	5'-TGCAGAAAATCTTAAGTGACAGCGG-3'
GSP-1 for fourth walking	5'-TGCAGAAAATCTTAAGTGACAGCGG-3'
GSP-2 for fourth walking	5'-CAAGGACTGGGGCAGCGAGCGG-3'
AP1	5'-GTAATACGACTCACTATAGGGC-3'
AP2	5'-ACTATAGGGCAGCGTGGT-3'

overlap. Then, rat IAP2 gene-specific primers were designed according to the 5' end sequence of the first walking product, for the second genomic walking. Four sequential rounds of genomic walking were performed to isolate the 3293 bp proximal 5'-flanking regions of rat IAP2. Advantage genomic PCR polymerase mix was purchased from Clontech for the PCR reactions.

5' Sequential deletion of the 3293 bp genomic segment

With the sequence of the 3293 bp 5'-flanking regions of rat IAP2, we generated its 5' sequential deletion mutants by PCR. Primers for these PCR reactions are indicated in Figure 3 (see below). Extra bases of *Xho*I and *Hind*III digestion sites were added at the 5' ends of forward and reverse primers, respectively. Inclusion of the digestion sites would facilitate subsequent cloning of the amplified DNA fragments into pGL3-Basic vectors (Promega, Madison, WI, U.S.A.). PCR supermix of high fidelity from Life Technologies and FailSafe PCR mix from Epicentre (Madison, WI, U.S.A.) were used for these reactions to minimize PCR errors. DNA fragments amplified by these PCR reactions were digested with *Xho*I and *Hind*III to prepare cohesive ends. Finally, the digested fragments were cloned into *Xho*I/*Hind*III-linearized pGL3-Basic by standard procedures. Cloned inserts were sequenced to verify the identity of DNA sequences.

Deletion of CREB and Sp-1 sites from 5'-flanking regions of rat IAP2

CREB and Sp-1 elements were deleted from the 1.8 kb rat IAP2 flanking sequence by PCR-based site-directed mutagenesis [41]. This was accomplished in two steps. First, upstream and downstream DNA fragments with deletions were amplified separately by PCR, using templates of pGL3 vectors harbouring 1.8 kb IAP2 flanking sequence. PCR primers were as follows with deletions shown in lower case. Amplification of the upstream fragment for CREB site deletion, forward (5'-CTA GCA AAA TAG GCT GTC CC-3') and reverse (CREB deletion primer 1, 5'-CCA GTA AGA CGT TAA GGtgactgacctgacctc AGC GGG CGC ACG-3'); amplification of the downstream fragment for CREB site deletion, forward (CREB deletion primer 2, 5'-CGT GCG CCC GCT Gactgacctgacctc TTA ACG TCT TAC TGG-3') and reverse (5'-CTT TAT GTT TTT GGC GTC TTC-3'); amplification of the upstream fragment for Sp-1 site deletion, forward (5'-CTA GCA AAA TAG GCT GTC CC-3') and reverse (Sp-1 deletion primer 1, 5'-GCA ATG ATG GAC

GGA GggcggggAC TGT GCG CCT GCG-3'); amplification of the downstream fragment for Sp-1 site deletion, forward (Sp-1 deletion primer 2, 5'-CGC AGG CGC ACA GTcccgccC TCC GTC CAT CAT TGC-3') and reverse (5'-CTT TAT GTT TTT GGC GTC TTC-3'). The amplified DNA fragments were sequenced. As expected from the primer design, the 3'-end sequence of the upstream fragments overlapped with 5' end of the downstream fragments. Moreover, deletions were introduced in the overlapping sequences through the deletion primers. In the second step, equal numbers of moles of upstream fragments and downstream fragments were mixed. The DNA mixture was used as a template to PCR-amplify the 1.8 kb genomic fragment containing CREB or Sp-1 deletions, using the primer pair, forward (5'-CTA GCA AAA TAG GCT GTC CC-3')/reverse (5'-CTT TAT GTT TTT GGC GTC TTC-3'). The amplified DNA fragments were cloned into the reporter gene vector pGL3-Basic, and deletions verified by sequencing.

Measurement of promoter activity for genomic DNA with reporter-gene vectors

We determined the promoter activity of isolated 5'-flanking regions of rat IAP2, using the luciferase reporter gene vector pGL3-Basic. pGL3-Basic is promoterless but contains a coding sequence for firefly luciferase. Proper insertion of sequences with promoter activity into pGL3-Basic will lead to expression of firefly luciferase. Promoter activity of the cloned sequences was indicated by the expression of luciferase in transfected cells. Lipofectamine-Plus (Life Technologies) was used to facilitate transfection according to the manufacturer's instructions. Briefly, cells were seeded at low density and transfected with pGL3-Basic harbouring 5'-flanking sequences for rat IAP2. As an internal control, pRL-TK vector was co-transfected and led to constitutive expression of *Renilla* luciferase. Then, 24 h later, the cells were lysed and the activities of firefly and *Renilla* luciferases were measured independently with the Dual-Luciferase Reporter assay system (Promega). The activity of firefly luciferase was normalized by the activity of *Renilla* luciferase to indicate promoter activity of cloned sequences.

Electrophoretic mobility-shift assay (EMSA)

Oligonucleotide probes of 24–26 bp were designed according to the sequence of the rat IAP2 gene promoter. The probes were ³²P-labelled with [γ -³²P]ATP and T4 polynucleotide kinase. Nuclear extracts were prepared from HEK-293 cells or RPTCs by the 'mini-extraction' method of Schreiber et al. [42]. EMSA was conducted as described previously [43]. Briefly, 6 μ g of nuclear extract was incubated for 20 min at room temperature with 5 \times 10⁴ c.p.m. of labelled probes in 20 ml of binding buffer containing 10 mM Tris/HCl, pH 7.6, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 1 mg/ml BSA and 2 mg of poly-d(I-C). For supershift assays, 2 μ g of specific antibodies were added and the reaction continued for 30 min. Samples were resolved by electrophoresis in 5% non-denaturing polyacrylamide gels. For competition experiments, nuclear extract was pre-incubated with competitor DNA for 10 min at 4 °C before addition of the labelled probe.

Biochemical analyses

Northern hybridization was performed by the procedure described in our previous studies [35], using NorthernMax kits from Ambion (Austin, TX, U.S.A.). The rat multiple tissue blots were purchased from Clontech. Probes for the hybridization

contained a cDNA sequence of rat IAP2 and were 32 P-labelled using the Ready-To-Go random-labelling beads (Amersham Pharmacia Biotech, Piscataway, NJ, U.S.A.). Immunoblot analysis of proteins was carried out by standard procedures.

RESULTS AND DISCUSSION

Isolation of the full-length cDNA of rat IAP2

The full-length cDNA of rat IAP2 was isolated by the RACE technique [37,38] (refer to the Materials and methods section

for technical details). The sequence of the cDNA has been deposited in GenBank under the accession number AF190020. The longest open reading frame of rat IAP2 encodes a protein of 589 amino acids, which displays the characteristic structural features of IAPs with three BIR domains at its N-terminus and one RING finger at the C-terminus (Figure 1). At the protein level, rat IAP2 shares 89 and 85% homology with mouse and human IAP2, respectively (Figure 1). Transfection of HEK-293 cells with the isolated rat IAP2 cDNA led to IAP2 protein expression (results not shown).

		BIR1	
rIAP2	-----MENSTVLSNWTKENKEKMKYDFSCELYRMSTYSAFPRGV		39
mIAP2	MDKTVSQRLGQGTTLHQKLRIMEKSTILSNWTKESSEKMKDFDFSCELYRMSTYSAFPRGV		60
hIAP2	MHKTASQRLFPGPSYQNIKSI MEDSTILSDWTNSNKQMKYDFSCELYRMSTYSTFPAGV		60
		.*::	
rIAP2	PVSESLARAGFYITGVNDKVKCFCCGLMLDNWKQGDSPTEKHRQFYPCSFVQTLTLLSGG		99
mIAP2	PVSESLARAGFYITGVNDKVKCFCCGLMLDNWKQGDSPVEKHRQFYPCSFVQTLTLLSAS		120
hIAP2	PVSESLARAGFYITGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPCSFQIQLVLSAS		120
		*****:**:	
rIAP2	LQSAAKNTSPAKSRFAHSLP--LEQG---GIHSSLPSNPLNSRAVEDFS--LRMNPCSYA		152
mIAP2	LQSPSKNMPVKSRFAHSSP--LERG---GIHSLCSSLNSRAVEDFS--SRMDPCSYA		173
hIAP2	LGSTSKNTSPMRNSFAHSLSPLEHSSLSFGSYSLPPNPLNSRAVEDISSSRINPYSYA		180
		.:**:	
		BIR2	
rIAP2	MSTEEARFLSYSMWPLSFLSPAELAKAGFYITGPGDRVACFACGGKLSNWPNDPDLSEH		212
mIAP2	MSTEEARFLTYSMWPLSFLSPAELARAGFYIIGPGDRVACFACGGKLSNWPDKDAMSEH		233
hIAP2	MSTEEARFLTYHMWPLTFLSPSELARAGFYIIGPGDRVACFACGGKLSNWPDKDAMSEH		240
		*****:**:	
		BIR3	
rIAP2	RRHFPHCFLENTSETQRFSVSNLSMQTHSARMSTFLYWPSSVLVQPEQLASAGFYVDH		272
mIAP2	RRHFPHCFLENTSETQRFSISNLSMQTHSARLRFTFLYWPSPVPVQPEQLASAGFYVDR		293
hIAP2	RRHFPHCFLENTSETLRFSISNLSMQTHAARMRTFMYWPSSVPVQPEQLASAGFYVGR		300
		*****:**:	
rIAP2	NDDVKCFCCDGGILRCWEPGDDPWIEHAKWFFRCEFLIRMKQGEFVDEIQARYPHLLEQLL		332
mIAP2	NDDVKCFCCDGGILRCWEPGDDPWIEHAKWFFRCEFLIRMKQGEFVDEIQARYPHLLEQLL		353
hIAP2	NDDVKCFGCDGGILRCWESGDDPWIEHAKWFFRCEFLIRMKQGEFVDEIQGRYPHLLEQLL		360
		*****:**:	
rIAP2	STSDTSEENADP--PVVHLGPGENW-EDAVMMNTPVVKAALDMGFSRSLVRQTVQRQIL		389
mIAP2	STSDTPGEENADPTEVVFHFGPGESS-KDVVMMSTPVVKAALDMGFSRSLVRQTVQRQIL		412
hIAP2	STSDTTGEENADP--PIIHFGPGESSSEDAVMMNTPVVKSALEMGNRDLVKQTVLTKIL		418
		*****:**:	
rIAP2	ATGENYRTVSDIVSALLNAEDERREEKERQSEETASGDSLIRKNRMALFQQLTTCVPIPI		449
mIAP2	ATGENYRTVNDIVSVLLNAEDERREEKERQTEEMASGDSLIRKNRMALFQQLTHVLPPI		472
hIAP2	TTGENYKTVNDIVSALLNAEDEKREEKEKQAEEMASDDLIRKNRMALFQQLTTCVLPPI		478
		*****:**:	
rIAP2	LDDLLEASVLTKEEHDIIKQKTQIPLQARELIDTILVKGNAAASVFNKSLKEVDSTLYEH		509
mIAP2	LDNLLASVITKQEHDIKQKTQIPLQARELIDTVLVKGNAAANIFKNKSLKEIDSTLYEN		532
hIAP2	LDNLLKANVINKQEHDIKQKTQIPLQARELIDTIWVKGNAAANIFKNKSLKEIDSTLYEN		538
		::	
		RING finger	
rIAP2	LFVEKTMKYIPTEDVSGLSLEEQLRRLQEERTCKVCMDEVSVIFPCGHLVVCRECAPS		569
mIAP2	LFVEKNMKYIPTEDVSGLSLEEQLRRLQEERTCKVCMDEVSVIFPCGHLVVCQECAPS		592
hIAP2	LFVDKNMKYIPTEDVSGLSLEEQLRRLQEERTCKVCMDEVSVIFPCGHLVVCQECAPS		598
		::	
rIAP2	LRKCPICRGTIKGTVRTFLS		589
mIAP2	LRKCPICRGTIKGTVRTFLS		612
hIAP2	LRKCPICRGIIKGTVRTFLS		618
		*****:*:*:*:*:*:*:*:*:*:*:	

Figure 1 Amino acid sequences of rat, mouse and human IAP2s

The deduced amino acid sequence of rat (r) IAP2 was aligned with the sequences of mouse (m) and human (h) IAP2 using CLUSTAL W software [46]. Conservations are indicated below the sequence: * for fully conserved residues; : for strong conservations; . for weak conservations. N-terminal BIR domains and the C-terminal RING finger motif are also indicated. Significant homology is shown between rat, mouse and human IAP2s (GenBank accession numbers AF190020, U88909 and U45879).




Figure 2 Rat IAP2 expression *in vivo* shown by Northern hybridization

Probes for Northern hybridization were prepared by ^{32}P -labelling of a cDNA fragment within the rat IAP2 coding region using Ready-To-Go DNA-labelling beads (Amersham Pharmacia Biotech). Rat multiple tissue blots from Clontech were hybridized with the cDNA probe at high stringency. The blots were subsequently stripped and reprobred with a β -actin cDNA probe to assess sample loading. Note that actin hybridization detected ≈ 1.6 kb transcripts in heart and skeletal muscles. According to Clontech, manufacturer of the blot, this was not due to RNA degradation but to probe hybridization to other isoforms of actin. To examine IAP2 expression in RPTCs, mRNA was isolated, resolved by denaturing agarose-gel electrophoresis ($2 \mu\text{g}/\text{lane}$) and transferred to nylon membranes. The blots were subsequently hybridized with the rat IAP2 cDNA probe, showing a major transcript of ≈ 3.5 kb.

Expression of rat IAP2 *in vivo*

By Northern hybridization, we detected a major rat IAP2 transcript of ≈ 3.5 kb in RPTCs (Figure 2). The size of this transcript is comparable with the full-length cDNA (3290 bp) that we have isolated. To examine IAP2 expression *in vivo*, we performed Northern hybridizations of rat multiple tissue blots. The hybridization probe was prepared by ^{32}P -labelling of a cDNA fragment within the rat IAP2 coding region. As shown in Figure 2, the 3.5 kb IAP2 transcript was detected in all rat tissues examined, with the most in testis and abundant expression in brain and liver, moderate expression in heart, spleen and kidney, and the least in lung and skeletal muscle. In addition, a larger transcript of ≈ 5 kb was also shown in all tissues except the heart. Of interest, two smaller transcripts were also expressed abundantly in rat testis (Figure 2). Whether these transcripts are alternatively spliced forms of rat IAP2 remains to be determined.

Isolation of the proximal 5'-flanking sequence of rat IAP2

With the sequence of rat IAP2 full-length cDNA, we subsequently isolated 5'-flanking genomic regions of this gene. This was accomplished by the procedure of genomic walking [39,40] (see the Materials and methods section for technical details). Four rounds of genomic walking led to the isolation of a 3293 bp proximal 5'-flanking region of rat IAP2. The sequence of this region has been submitted to GenBank under the accession number AY027668 (Figure 3, top panel). Analysis of the genomic sequence by the database SIGNAL SCAN [44] suggests the

presence of the key transcriptional element TFIID within 26 bp from the transcription-initiation site (Figure 3, bottom panel). TATA boxes were also identified, although they are 600–700 bp away. In addition, potential binding sites for numerous known transcription factors, such as nuclear factor-1, glucocorticoid receptor, Pit-1, c-Myc and CREB, are present. Of interest, four core binding sites for the hypoxia-responsive transcription factor HIF-1 [45] were also found at positions -1055 , -1195 , -1727 and -2236 (Figure 3, bottom panel). Our recent studies have demonstrated a striking induction of IAP2 by severe hypoxia; however, this induction can be dissociated from HIF-1 [35]. When HIF-1 was activated pharmacologically or by 2% oxygen, IAP2 was not induced. On the other hand, IAP2 could be induced strongly by severe hypoxia in HIF-1-deficient cells. Thus, the HIF-1-binding elements present in the 5'-flanking regions of IAP2 could be silent under those conditions.

Promoter activity of rat IAP2 5'-flanking sequence

To examine whether the 5'-flanking regions isolated by genomic walking contain the gene promoter of rat IAP2, we determined the promoter efficiency of the sequences using the luciferase reporter gene vector, pGL3-Basic. We initially dissected the IAP2-flanking region by PCR-based sequential 5' deletions. Primers for the PCR reactions were designed according to the 3.3 kb genomic segment (Figure 3, top panel, underlined sequences). The PCR reactions amplified genomic DNA fragments immediately upstream of IAP2 cDNA of lengths 0.13, 0.29, 0.45, 0.85, 1.6, 2.0 and 3.1 kb. These fragments were subsequently cloned into pGL3-Basic for transfection (Figure 4A). Firefly luciferase activity in transfected cells was monitored to indicate promoter efficiency of the cloned genomic sequences, and the results are shown in Figure 4. Transfection of HEK-293 and 3T3 cells with pGL3-Basic harbouring the 0.13 kb genomic segment led to 13- and 38-fold increases in promoter activity, respectively (Figures 4B and 4C). Promoter efficiency decreased thereafter, up to 1.6 kb. To our surprise, when the sequence was extended from 1.6 to 2.0 kb, a remarkable increase in promoter activity was detected. In HEK-293 cells, the activity was 140-fold over control, and in 3T3 cells, 270-fold (Figures 4B and 4C). Further extension of the sequence to 3.1 kb led to decreases in promoter efficiency (Figure 4). Together, these results demonstrate significant promoter activity for the IAP2 5'-flanking regions isolated by genomic walking.

Identification of an enhancer sequence in rat IAP2 promoter region

Our results have shown an abrupt increase in promoter activity between 1.6 and 2.0 kb within the rat IAP2 promoter region (Figure 4). To identify further the enhancer elements, we dissected the sequence by ≈ 100 bp using PCR-based methodology. The amplified DNA fragments were cloned into pGL3-Basic for transfection to determine their promoter activity. The results are shown in Figure 5. Significant increases in promoter activity were detected when the sequence was extended from 1.6 to 1.8 kb; further extensions to 1.9 or 2.0 kb resulted in reductions. These analyses indicate that the enhancer elements are localized within the 200 bp between 1.6 and 1.8 kb.

Binding of CREB and Sp-1 to the enhancer sequence

The data presented in the above section have narrowed down the enhancer sequence to ≈ 200 bp (Figure 5). We subsequently analysed this 200 bp sequence using databases, and identified a




Figure 4 Promoter activity of the 5'-flanking genomic sequence of rat IAP2

(A) 5' Sequential deletion constructs cloned into pGL3-Basic. Seven 5' sequential deletion constructs (0.13–3.1 kb) were generated by PCR. Primers for the PCR reactions were designed according to the 3293 bp genomic sequence isolated by genomic walking, and have been underlined in Figure 3 (top panel). The deletion constructs were cloned into pGL3-Basic. (B, C) Promoter activity of rat IAP2-flanking regions in transfected HEK-293 (B) and 3T3 (C) cells. Cells were transfected with pGL3-Basic empty vector, or the vector containing 0.13–3.1 kb IAP2-flanking regions. Promoter activity was indicated by firefly luciferase expression in transfected cells (see the Materials and methods section for details). The values obtained from control transfection with empty pGL3-Basic were arbitrarily set at 1. The experiments were repeated three times with duplicates for each condition. Data points are means \pm S.D. The results demonstrate significant promoter activity for the 5'-flanking regions of rat IAP2 that were isolated by genomic walking.




Figure 5 Promoter activity of 1.6–2.0 kb 5'-flanking regions of rat IAP2

The genomic fragments were PCR-amplified using primers indicated in Figure 3 (top panel), and cloned into pGL3-Basic (A). Empty pGL3-Basic or pGL3-Basic containing the genomic fragments were transfected into HEK-293 (B) or 3T3 (C) cells. Expression of firefly luciferase was analysed to indicate promoter activity of transfected fragments. The values obtained from control transfection with empty pGL3-Basic were arbitrarily set at 1. The experiments were repeated three times with duplicates for each condition. Data points are means \pm S.D. The results show significant increases in promoter activity during the sequence extension from 1.6 to 1.8 kb, indicating the presence of enhancer elements within the 200 bp.




Figure 6 Analysis of the 200 bp enhancer sequence

The sequence was analysed for potential transcription-factor binding sites, using the database SIGNAL SCAN. Potential CREB-, ATF- and Sp-1-binding sites are shaded. Sequences written in lower-case letters were deleted to test their involvement in the enhancer activity (Figure 8). Underlined sequences were used to design PCR primers to generate 1.7 and 1.8 kb genomic fragments.

led to the supershift of a specific complex of high molecular mass (Figure 7, lane 12). The EMSA results suggest that CREB and Sp-1 can bind to the enhancer sequence and may regulate the promoter activity of IAP2.

CREB-binding site as a critical element for the enhancer sequence

To identify further the key enhancer elements, we introduced specific deletions at the CREB/ATF and Sp-1 sites in the 1.8 kb fragment. The intact fragment and the mutants were then transfected into HEK-293 cells to measure their promoter activities. As shown in Figure 8, deletion of CREB/ATF sites led to marked decreases in promoter activity of the 1.8 kb fragment, whereas Sp-1 deletion had little or no effect. Similar results were obtained for transfection of 3T3 cells (results not shown). These experiments, along with the results showing CREB binding to the enhancer sequence (Figure 7), suggest a critical role for the CREB site in the enhancer activity.

Activation of IAP2 gene promoter by severe hypoxia and not by CoCl_2 or desferrioxamine

Expression of IAP2 is induced by severe hypoxia or anoxia in a remarkable manner [35]. To a large extent, this induction depends on the activation of gene transcription. Further investigations have dissociated IAP2 induction from the ubiquitous hypoxia-responsive transcription factor HIF-1 [35]. These results suggest a novel mechanism for hypoxic regulation of the IAP2 gene,




Figure 7 EMSA analysis of CREB-, ATF- and Sp-1-binding to the enhancer sequence

Nuclear extracts of HEK-293 cells were incubated with ³²P-labelled oligonucleotide probes encompassing the CREB, ATF or Sp-1 site of the enhancer sequence. DNA sequences of the probe were ³²P-IAP2-CREB (gtgcgccgctgacgtcaccgcacg), ³²P-IAP2-ATF (gtcaccgcacgtcaccctaacgctc) and ³²P-IAP2-Sp-1 (cgcacagtcgccgcccctccgctccatc). For supershift, antibodies to CREB (C; lane 3), ATF (A; lane 8) or Sp-1 (S; lane 12) were added during nuclear-extract incubation. For competition, excess amounts (100 ×) of unlabelled oligonucleotides were added along with the ³²P-labelled probes (lanes 4, 7 and 10). An unlabelled oligonucleotide with a mutated CREB site (lane 5; m; DNA sequence, gtgcgccgctgacgtcaccgcacg) and a consensus Sp-1-binding sequence (lane 11; c; DNA sequence, attcgcggggcggggcgcgag) were also tested for competition with the ³²P-labelled probes. EMSA was conducted as described in the Materials and methods section. Major DNA-protein complexes are indicated by arrows. Supershift complexes are indicated by arrowheads with SS₁ for CREB supershift and SS₂ for Sp-1 supershift. Apparent DNA-protein-complex formation was shown for the probes containing CREB or Sp-1 sites (lanes 2 and 9). Addition of CREB and Sp-1 antibodies led to supershift of the complexes (lanes 3 and 12).




Figure 8 Loss of enhancer activity after CREB-site deletion

Deletions of CREB/ATF- or Sp-1-binding sites were introduced by PCR-based site-directed mutagenesis. The deleted sequences are shown in Figure 6 in lower-case letters. The deletions are indicated in this Figure by crosses. The intact fragments and deletion mutants were cloned into pGL3-Basic for transfection into HEK-293 cells. Expression of firefly luciferase in transfected cells was analysed to indicate promoter activity of the genomic DNA fragments. The values obtained from control transfection with empty pGL3-Basic were arbitrarily set at 1. The experiments were repeated three times with duplicates for each condition. Data points indicate means ± S.D. The results show that deletion of CREB/ATF- but not Sp-1-binding sites led to significant decreases in promoter activity of the 1.8 kb fragment, suggesting a role for the CREB/ATF elements in the enhancer activity of the sequence.

probably at the promoter level. Therefore, our subsequent studies examined whether the isolated IAP2 promoter contains functional *cis*-acting elements that are responsive to severe hypoxia. pGL3 vectors harbouring promoter segments of various lengths were transfected into rat adrenal pheochromocytoma PC12 cells. The experimental groups of cells were subjected to 3 h of hypoxic incubation, whereas the control cells were incubated under normal oxygen. Luciferase expression was determined at the end of incubation to indicate promoter efficiency. Results from a




Figure 9 Activation of IAP2 gene promoter by severe hypoxia and not by CoCl₂ or desferrioxamine

(A) IAP2 gene promoter is activated by severe hypoxia. PC12 cells were transfected with pGL3-Basic vectors harbouring 1.8 or 3.1 kb rat IAP2 promoter sequences. One group of transfected cells was subjected to 3 h of hypoxic incubation (−O₂), while the other group of cells was incubated under normal oxygen as the control (+O₂). (B) IAP2 gene promoter is not activated by CoCl₂ or desferrioxamine. Cells were transfected with pGL3-Basic vectors harbouring 3.1 kb rat IAP2 promoter sequence. Transfected cells were incubated for 6 h under normal oxygen without (+O₂) or with 100 μM CoCl₂ (CoCl₂+O₂) or desferrioxamine (DFO+O₂). After incubation, cells were lysed and firefly luciferase activity in the lysates was measured to indicate promoter activity, as described in the Materials and methods section. Significantly higher promoter activity was shown for the genomic fragments after hypoxic incubation, indicating activation of the IAP2 gene promoter by severe hypoxia. On the other hand, the gene promoter was not activated by CoCl₂ or desferrioxamine, negating a role for HIF-1 in IAP2 gene regulation.

typical experiment are shown in Figure 9(A). Promoter activity within hypoxic cells was 4.6- and 3.2-fold above the control level for the 1.8 and 3.1 kb segments respectively, indicating significant activation of the IAP2 gene promoter by severe hypoxia. In sharp contrast, pharmacological inducers of HIF-1, including CoCl₂ and desferrioxamine, activated HIF-1 [35,45], but not the gene promoter of IAP2 (Figure 9B). These results are in support of our previous observations of hypoxic induction of IAP2 [35], and further negate the role of HIF-1 in this inductive response.

Conclusions

The current study has cloned the full-length cDNA of rat IAP2 from kidney proximal tubular cells. With significant homology to mouse and human, rat IAP2 is characterized by its structure, including typical BIR domains and a RING motif. Expression of rat IAP2 *in vivo* varies among different tissues, with a major transcript of ≈ 3.5 kb. With the cDNA sequence, we have subsequently isolated 3293 bp of the proximal 5'-flanking region of the IAP2 gene. Analysis by reporter-gene vectors has demonstrated significant promoter activity for the genomic sequence. This is also the first promoter region isolated for this gene. The study has further identified an enhancer sequence of ≈ 200 bp in the gene promoter, which might have a significant role in IAP2 regulation. The CREB-binding element within this sequence appears to be critical for the enhancer activity. Of significance, the rat IAP2 gene promoter can be activated by severe hypoxia or anoxia, conditions shown to stimulate IAP2 expression. The findings indicate the presence of critical *cis*-acting elements in the gene promoter, which are responsible for IAP2 regulation under pathophysiological situations, including hypoxia. Certainly, identification of such elements would be the focus of further investigations.

We thank the Center for Advanced DNA Technologies in the University of Texas Health Science Center for assistance in oligonucleotide synthesis and DNA sequencing. We also thank Dr U. Hopfer (Case Western Reserve University,

Cleveland, OH, U.S.A.) for providing rat kidney proximal tubular cells. Z.D. is the recipient of the Lyndon Baines Johnson Research Award from the American Heart Association, the Patricia W. Robinson Young Investigator of the National Kidney Foundation and the Carl W. Gottschalk Research Scholar of the American Society of Nephrology. This work was supported in part by grants from the Texas Advanced Research Program (Z.D.), the American Heart Association (Z.D.), the National Kidney Foundation (Z.D.), the American Society of Nephrology (Z.D.) and the National Institutes of Health (DK58831 to Z.D. and DK37139 to M.A.V.).

REFERENCES

- Miller, L. K. (1999) An exegesis of IAPs: salvation and surprises from BIR motifs. *Trends Cell Biol.* **9**, 323–328
- LaCasse, E. C., Baird, S., Korneluk, R. G. and MacKenzie, A. E. (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. *Oncogene* **17**, 3247–3259
- Deveraux, Q. L. and Reed, J. C. (1999) IAP family proteins—suppressors of apoptosis. *Genes Dev.* **13**, 239–252
- Hay, B. A. (2000) Understanding IAP function and regulation: a view from *Drosophila*. *Cell Death Differ.* **7**, 1045–1056
- Green, D. R. (2000) Apoptotic pathways: paper wraps stone blunts scissors. *Cell* **102**, 1–4
- Yamaguchi, K., Nagai, S., Ninomiya-Tsuji, J., Nishita, M., Tamai, K., Irie, K., Ueno, N., Nishida, E., Shibuya, H. and Matsumoto, K. (1999) XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. *EMBO J.* **18**, 179–187
- Reffey, S. B., Wurthner, J. U., Parks, W. T., Roberts, A. B. and Duckett, C. S. (2001) X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. *J. Biol. Chem.* **276**, 26542–26549
- Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C. and Altieri, D. C. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature (London)* **396**, 580–584
- Fraser, A. G., James, C., Evan, G. I. and Hengartner, M. O. (1999) *Caenorhabditis elegans* inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. *Curr. Biol.* **9**, 292–301
- Speliotes, E. K., Uren, A., Vaux, D. and Horvitz, H. R. (2000) The survivin-like *C. elegans* BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. *Mol. Cell* **6**, 211–223
- Uren, A. G., Wong, L., Pakusch, M., Fowler, K. J., Burrows, F. J., Vaux, D. L. and Choo, K. H. (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. *Curr. Biol.* **10**, 1319–1328
- Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M. and Ashwell, J. D. (2000) Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science* **288**, 874–877
- Suzuki, Y., Nakabayashi, Y. and Takahashi, R. (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 8662–8667
- Ambrosini, G., Adida, C. and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat. Med.* **3**, 917–921
- Roy, N., Mahadevan, M. S., McLean, M., Shutter, G., Yaraghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C., Kang, X. et al. (1995) The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* **80**, 167–178
- Xu, D. G., Crocker, S. J., Doucet, J. P., St-Jean, M., Tamai, K., Hakim, A. M., Ikeda, J. E., Liston, P., Thompson, C. S., Korneluk, R. G. et al. (1997) Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. *Nat. Med.* **3**, 997–1004
- Crook, N. E., Clem, R. J. and Miller, L. K. (1993) An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J. Virol.* **67**, 2168–2174
- Rothe, M., Pan, M. G., Henzel, W. J., Ayres, T. M. and Goeddel, D. V. (1995) The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* **83**, 1243–1252
- Hay, B. A., Wassarman, D. A. and Rubin, G. M. (1995) *Drosophila* homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. *Cell* **83**, 1253–1262
- Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., Cherton-Horvat, G., Farahani, R., McLean, M., Ikeda, J. E., MacKenzie, A. and Korneluk, R. G. (1996) Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature (London)* **379**, 349–353
- Duckett, C. S., Nava, V. E., Gedrich, R. W., Clem, R. J., Van Dongen, J. L., Gilfillan, M. C., Shiels, H., Hardwick, J. M. and Thompson, C. B. (1996) A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. *EMBO J.* **15**, 2685–2694
- Uren, A. G., Pakusch, M., Hawkins, C. J., Puls, K. L. and Vaux, D. L. (1996) Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 4974–4978
- You, M., Ku, P. T., Hrdlickova, R. and Bose, Jr, H. R. (1997) ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. *Mol. Cell Biol.* **17**, 7328–7341
- Stehlik, C., de Martin, R., Binder, B. R. and Lipp, J. (1998) Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B. *Biochem. Biophys. Res. Commun.* **243**, 827–832
- Silke, J. and Vaux, D. L. (2001) Two kinds of BIR-containing protein – inhibitors of apoptosis, or required for mitosis. *J. Cell Sci.* **114**, 1821–1827
- Chai, J., Shiozaki, E., Srinivasula, S. M., Wu, Q., Dataa, P., Alnemri, E. S. and Shi, Y. (2001) Structural basis of caspase-7 inhibition by XIAP. *Cell* **104**, 769–780
- Huang, Y., Park, Y. C., Rich, R. L., Segal, D., Myszk, D. G. and Wu, H. (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. *Cell* **104**, 781–790
- Riedl, S. J., Renatus, M., Schwarzenbacher, R., Zhou, Q., Sun, C., Fesik, S. W., Liddington, R. C. and Salvesen, G. S. (2001) Structural basis for the inhibition of caspase-3 by XIAP. *Cell* **104**, 791–800
- Takahashi, R., Deveraux, Q., Tamm, I., Welsh, K., Assa-Munt, N., Salvesen, G. S. and Reed, J. C. (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. *J. Biol. Chem.* **273**, 7787–7790
- Vucic, D., Kaiser, W. J. and Miller, L. K. (1998) A mutational analysis of the baculovirus inhibitor of apoptosis Op-IAP. *J. Biol. Chem.* **273**, 33915–33921
- Borden, K. L. (2000) RING domains: master builders of molecular scaffolds? *J. Mol. Biol.* **295**, 1103–1112
- Huang, H., Joazeiro, C. A., Bonfoco, E., Kamada, S., Leverson, J. D. and Hunter, T. (2000) The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. *J. Biol. Chem.* **275**, 26661–26664
- Holcik, M., Lefebvre, C., Yeh, C., Chow, T. and Korneluk, R. G. (1999) A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. *Nat. Cell Biol.* **1**, 190–192
- Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. and Baldwin, Jr, A. S. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science* **281**, 1680–1683
- Dong, Z., Venkatachalam, M. A., Wang, J., Patel, Y., Saikumar, P., Semenza, G. L., Force, T. and Nishiyama, J. (2001) Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. *J. Biol. Chem.* **276**, 18702–18709
- Dong, Z., Saikumar, P., Patel, Y., Weinberg, J. M. and Venkatachalam, M. A. (2000) Serine protease inhibitors suppress cytochrome c-mediated caspase-9 activation and apoptosis during hypoxia-reoxygenation. *Biochem. J.* **347**, 669–677
- Frohman, M. A., Dush, M. K. and Martin, G. R. (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. *Proc. Natl. Acad. Sci. U.S.A.* **85**, 8998–9002
- Chenich, A., Diachenko, L., Moqadam, F., Tarabykin, V., Lukyanov, S. and Siebert, P. D. (1996) Full-length cDNA cloning and determination of mRNA 5' and 3' ends by amplification of adaptor-ligated cDNA. *Biotechniques* **21**, 526–534
- Siebert, P. D., Chenich, A., Kellogg, D. E., Lukyanov, K. A. and Lukyanov, S. A. (1995) An improved PCR method for walking in uncloned genomic DNA. *Nucleic Acids Res.* **23**, 1087–1088
- Nishiyama, J., Yi, X., Venkatachalam, M. A. and Dong, Z. (2001) cDNA cloning and promoter analysis of rat caspase-9. *Biochem. J.* **360**, 49–56
- Tomic-Canic, M., Berner, F. and Blumenberg, M. (1996) A simple method to introduce internal deletions or mutations into any position of a target DNA sequence. *Methods Mol. Biol.* **57**, 249–257
- Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. *Nucleic Acids Res.* **17**, 6419
- Li, S. L., Valente, A. J., Wang, L., Gamez, M. J. and Clark, R. A. (2001) Transcriptional regulation of the p67phox Gene. Role of AP-1 in concert with myeloid-specific transcription factors. *J. Biol. Chem.* **276**, 39368–39378
- Prestridge, D. S. (2000) Computer software for eukaryotic promoter analysis. *Methods Mol. Biol.* **130**, 265–295
- Semenza, G. L. (1999) Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. *Annu. Rev. Cell Dev. Biol.* **15**, 551–578
- Higgins, D. G., Thompson, J. D. and Gibson, T. J. (1996) Using CLUSTAL for multiple sequence alignments. *Methods Enzymol.* **266**, 383–402